Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser(University of California, San Francisco), Ludwig Kappos(University Hospital of Basel), Algirdas Kakarieka(Multiple Sclerosis Research Institute), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Heinz Wiendl(University Medical Center Freiburg), Gıancarlo Comı(Casa di Cura Columbus), Jorge Correale(Consejo Nacional de Investigaciones Científicas y Técnicas), Roman Willi(Multiple Sclerosis Research Institute), Davorka Tomic(Multiple Sclerosis Research Institute), Dieter A. Häring(Novartis (Switzerland)), David Leppert, Amit Bar‐Or(University of Pennsylvania), Anne H. Cross(Washington University in St. Louis), Ratnakar Pingili(Novartis (France)), Cécile Kerloëguen(Multiple Sclerosis Research Institute), Bingbing Li(Novartis (France)), Martin Merschhemke(Novartis (Switzerland)), Patricia K. Coyle(Multiple Sclerosis Research Institute), de Sèze(Hôpital d'Hautepierre), Jeffrey Cohen(Cleveland Clinic), Alexandra Goodyear(Novartis (France))
Cited by 706
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k